David Leppert

Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications

Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age‐ and <scp>BMI</scp> ‐Corrected <i>Z</i> Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response

Neurofilaments as biomarkers in neurological disorders — towards clinical application

Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials

Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis

Interleukin-3 coordinates glial-peripheral immune crosstalk to incite multiple sclerosis

Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study

Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension

Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury

Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis

A New Advanced<scp>MRI</scp>Biomarker for Remyelinated Lesions in Multiple Sclerosis

Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study

Early life serum neurofilament dynamics predict neurodevelopmental outcome of preterm infants

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Neurofilaments: neurobiological foundations for biomarker applications

Blood neurofilament light levels segregate treatment effects in multiple sclerosis

Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19

Association of Neuronal Injury Blood Marker Neurofilament light chain with mild-to-moderate COVID-19

Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis

Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses

Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients

Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome

Composite end points to assess delay of disability progression by MS treatments